Page 4 - Junshi Bioscience News Today

Hikma and Junshi Biosciences sign exclusive licensing agreement for cancer treatment drug toripalimab for the Middle East and North Africa region

SHANGHAI, China, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated

Investegate announcements from Junshi Biosciences, Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region

SHANGHAI, China, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading...

- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA - - Junshi Biosciences and Coherus are actively engaged in ongoing discussions... | December 25, 2022

- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA - - Junshi Biosciences and Coherus...

(RTTNews) - Shanghai Junshi Biosciences Co., Ltd and Coherus BioSciences Inc. (CHRS) said Sunday that they have not received an action letter from...

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) GlobeNewswire December 25, 2022 - FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the...

- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA - - Coherus and Junshi Biosciences...

24.12.2022 - - FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA - - Coherus and Junshi Biosciences are actively engaged in ongoing discussions with the FDA to support the inspections and gain ... Seite 1